dydrogesterone / Generic mfg. - LARVOL DELTA

Menopause Hormone Therapy in Women With Cardiovascular Risk Factors or Established Ischemic Heart Disease: A Joint FIGO and WHF Position Paper. (PubMed, Glob Heart) - "For those at high thromboembolic risk, transdermal estrogen, with micronized progesterone or dydrogesterone when needed, is considered the safest regimen. All primary and secondary prevention measures, including statins, should be continued. Managing the most complex cases warrants the adoption of a multidisciplinary approach between cardiologists, gynecologists, internists and primary care providers to offer the best possible care."

Journal • Review • Cardiovascular • Coronary Artery Disease • Gynecology • Heart Failure • Obstetrics • Women's Health

Oral dydrogesterone versus oral micronized progesterone: Interim analysis of a randomized controlled trial in pregnant women with threatened miscarriage. (PubMed, Int J Reprod Biomed) - "No AE was related to study medication. Compared to oral MP, oral DYD resulted in a numerically lower miscarriage rate and time to symptom resolution, concomitant to favorable decrease in Th1:Th2 ratio."

Journal • Oncology • Pain • IFNG • IL10 • IL4 • TNFA

Menopause hormone therapy in women with cardiovascular risk factors or established ischemic heart disease: A joint FIGO and WHF position paper. (PubMed, Int J Gynaecol Obstet) - "For those at high thromboembolic risk, transdermal estrogen, with micronized progesterone or dydrogesterone when needed, is considered the safest regimen. All primary and secondary prevention measures, including statins, should be continued. Managing the most complex cases warrants the adoption of a multidisciplinary approach between cardiologists, gynecologists, internists and primary care providers to offer the best possible care."

Journal • Cardiovascular • Coronary Artery Disease • Gynecology • Heart Failure • Obstetrics • Women's Health

Dydrogesterone and inflammatory marker regulation: a systematic review and quantitative meta-analysis. (PubMed, Gynecol Endocrinol) - "Evidence does not indicate increased inflammation, but certainty is very low. Larger, well-designed randomised controlled trials are needed to clarify its immunomodulatory effects."

Biomarker • Clinical • Journal • Retrospective data • Review • Inflammation • CRP • IL10 • IL6 • TNFA

Study on Efficacy and Safety of Dydrogesterone Monotherapy versus Combined with Vaginal Progesterone in Natural Cycle Frozen-thawed Embryo Transfer (ChiCTR) - P=N/A | N=1227 | Not yet recruiting | Sponsor: Northwest Women's and Children's Hospital; Northwest Women's and Children's Hospital

Monotherapy • New trial • Infertility • Sexual Disorders

Expanding the Horizons of Menopausal Hormone Therapy: A Narrative Review of Progestogen-Only and Testosterone-Only Strategies for Tailored Management. (PubMed, J Menopausal Med) - "Evidence suggests that progestogen-only therapy, particularly oral micronized progesterone (oP4), offers a robust alternative for alleviating vasomotor symptoms and sleep disturbances through its action on GABAergic neurosteroid pathways. Notably, observational data from large cohort studies, including the Etude Epidémiologique auprès de femmes de la Mutuelle Générale de l'Education Nationale study, suggest that oP4 and dydrogesterone are associated with a more favorable risk profile for venous thromboembolism and breast cancer than synthetic progestins used in combined hormone therapy...In the absence of approved female-specific testosterone products in South Korea, cautious off-label dosing and rigorous monitoring remain essential. Overall, monotherapy with progestogens or testosterone constitutes a vital component of tailored menopause management, if clinicians adhere to evidence-based protocols and remain aware of the current limitations in..."

Journal • Review • Breast Cancer • Cardiovascular • CNS Disorders • Oncology • Sexual Disorders • Sleep Disorder • Solid Tumor • Venous Thromboembolism

Combined Progesterone Administration Versus Single-Route Administration for Luteal Phase Support in IVF: A Narrative Review of Current Evidence. (PubMed, J Reprod Infertil) - "Most studies did not demonstrate statistically significant differences in outcomes between single-route and combined progesterone regimens, particularly when dydrogesterone was included. The physiological rationale for combined administration, offering both systemic and local endometrial support, is compelling. Further well-designed randomized controlled trials with standardized protocols are necessary to establish evidence-based guidelines for optimal LPS."

Journal • Review

Literature review of estradiol/dydrogesterone in perimenopausal and postmenopausal women. (PubMed, Climacteric) - "The findings of this literature review shed light on options for optimizing MHT treatment and doses for perimenopausal and postmenopausal women. Further research is warranted to confirm findings in women with high BMI."

Journal • Review • Breast Cancer • Cardiovascular • Genetic Disorders • Musculoskeletal Diseases • Obesity • Oncology • Rheumatology • Solid Tumor • Venous Thromboembolism • Women's Health

Tales from the clinic: options for perimenopausal bleeding, contraception and menopausal symptom control. (PubMed, Post Reprod Health) - "This article presents three cases of women presenting in the perimenopause where alternative medical management is offered with newer hormonal therapies: Drovelis, Dydrogesterone and Dienogest. In each case, consideration is made to the management of bleeding, perimenopausal symptom control, and provision of contraception."

Journal

Comparison between oral dydrogesterone versus no drugs in clinical outcome within the natural cycle-frozen-thawed embryo transfer cycle: a retrospective analysis. (PubMed, BMC Pregnancy Childbirth) - "30 mg/d oral dydrogesterone and no LPS revealed similar reproductive outcomes in NC-FET cycles in the study."

Clinical data • Journal • Retrospective data • Infertility • Sexual Disorders

Clinical Efficacy And Safety of Dydrogesterone In The Treatment Of Abnormal Uterine Bleeding During Puberty (clinicaltrials.gov) - P=N/A | N=240 | Recruiting | Sponsor: Guangdong Women and Children Hospital

HEOR • New trial • Women's Health

Natural vs. artificial cycle for frozen embryo transfer: impact on clinical and obstetric outcomes. (PubMed, JBRA Assist Reprod) - "True natural cycles were associated with significantly higher clinical pregnancy and live birth rates, as well as lower miscarriage rates, than artificial cycles in euploid frozen embryo transfer cycles."

Journal • Diabetes • Gestational Diabetes • Gynecology • Metabolic Disorders • Obstetrics • Uterine Leiomyoma • Women's Health

Progestogen-primed ovarian stimulation vs GnRH antagonists and/or agonists for women undergoing assisted reproduction: systematic review and meta-analysis. (PubMed, Ultrasound Obstet Gynecol) - "Current evidence of moderate-to-low certainty suggests that PPOS results in a higher number of oocytes and a higher live-birth rate in the first embryo-transfer cycle compared with a GnRH antagonist protocol. PPOS appears safe, with no case of severe OHSS observed across the analyzed cohorts. Given its oral administration, lower drug cost and demonstrated efficacy, PPOS represents a viable and potentially superior alternative to GnRH analogs for women undergoing ovarian stimulation for whom fresh-embryo transfer is not intended."

Journal • Retrospective data • Review • Gynecology • Obstetrics

A case of breast cancer with recurrent liver metastasis after surgery, treated with radiofrequency ablation followed by palbociclib, resulting in continued remission. (JBCS 2026) - "[Medical history] For 4 years prior to visiting our department, she had been receiving dydrogesterone and conjugated estrogen from the gynecology department of our hospital for menstrual irregularities and polycystic ovary syndrome, and autoimmune hepatitis had been diagnosed immediately before visiting our department...Postoperatively, radiation therapy was performed on the remaining breast, and adjuvant therapy with subcutaneous goserelin injections and oral tamoxifen was initiated...In this case, liver metastases appeared within one year post-surgery, and a poor prognosis was anticipated. However, because the metastases were solitary, local therapy was effective, and we believe that the CDK4/6 inhibitor, which had just become available, was beneficial."

Clinical • Surgery • Autoimmune Hepatitis • Breast Cancer • Gynecology • Hepatology • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Positive Breast Cancer • Immunology • Mucinous carcinoma • Oncology • Polyendocrine Metabolic Ovarian Syndrome • Solid Tumor • Women's Health • ER • HER-2 • PGR

Yang-Xue-An-Tai Decoction Treats URSA by Regulating the Differentiation of Proliferating Decidual Stromal Cells Through Multiple Targets. (PubMed, J Ethnopharmacol) - "Disordered proDSC differentiation correlates with defective decidualization and adverse pregnancy phenotypes in URSA mice. Multiple favorable cellular and molecular changes are observed alongside YXAT intervention, including recovered proDSC abundance, restored expression of the differentiation-associated gene Lgals1, and normalized abnormal NK cell-proDSC intercellular signaling. These correlative observations offer new insights into the clinical potential of YXAT and advance our understanding of TCM interventions against URSA."

Journal • GZMA • ITGB5 • LAMB2 • LAMC1 • LGALS1 • PARD3 • SPP1

GSDMD/Caspase-1-based evaluation of dydrogesterone in preventing recurrence after hysteroscopic endometrial polypectomy. (PubMed, Clinics (Sao Paulo)) - "Post-EP recurrence correlates with GSDMD/Caspase-1 levels, and integrating these markers enhances recurrence risk assessment."

Journal • Gynecology • Women's Health • CASP1

DYG-GONA: rFSH vs rFSH+rLH in Dydrogesterone-Based Progestin Protocol: A Prospective Study (clinicaltrials.gov) - P=N/A | N=202 | Completed | Sponsor: Centrum Clinic IVF Center | Recruiting ➔ Completed | N=300 ➔ 202

Enrollment change • Trial completion • Gynecology

Effects of Menopausal Hormone Therapy on Uterine Fibroids in Women During Menopausal Transition. (PubMed, Int J Womens Health) - "This retrospective observational study enrolled women during menopausal transition with uterine fibroids who received sequential menopausal hormone therapy (estradiol combined with dydrogesterone) at Nanjing Women and Children's Healthcare Hospital from January 2016 to August 2023...With regular surveillance and use of the lowest effective dose, MHT represents a safe and practical therapeutic choice. Additional prospective investigations are needed to characterize the long-term dynamic changes of fibroids associated with MHT."

Journal • Gynecology • Solid Tumor • Uterine Leiomyoma • Women's Health

Association between serum progesterone levels on the day of embryo transfer and clinical pregnancy outcomes in POSEIDON Group 1 patients. (PubMed, Front Endocrinol (Lausanne)) - "High serum P was linked to a lower clinical pregnancy rate in normal-weight patients, but not in overweight/obese patients. These findings support the implementation of individualized luteal support strategies based on serum P and BMI stratification."

Journal • Retrospective data • Obesity

Reproductive Outcomes in Programmed Ovulatory versus Modified Natural Cycle FET: A Propensity Score-Matched Analysis of Prospective and Retrospective Cohorts. (PubMed, Fertil Steril) - "Treatment outcomes did not differ significantly between PO-FET and mNC-FET regimens, suggesting that hCG may be unnecessary and that the protocol choice can align with patient and clinician preferences in a population of normo-ovulatory women."

Journal • Retrospective data

Effect of vaginal estrogen supplementation for luteal phase support in the GnRH antagonist protocol on pregnancy outcomes for IVF/ICSI cycles: a randomized controlled trial. (PubMed, Hum Reprod Open) - P4 | "The addition of vaginal luteal estradiol supplementation in GnRH antagonist cycles improves embryo implantation and clinical pregnancy rates, yet fails to demonstrate significant benefits in ongoing pregnancy or live birth outcomes for IVF/ICSI patients. This intervention was associated with an increased risk of ICP compared to that in progesterone-only controls, highlighting the need for clinical vigilance regarding maternal safety. Although there was no significant between-group difference in the incidence of ICP in the sensitivity analysis, this null finding is likely due to the small number of events and limited statistical power. Notably, ICP should remain a safety signal that warrants attention when estrogen supplementation is administered during early pregnancy. These findings indicate that while estradiol supplementation may enhance early reproductive endpoints, its clinical utility remains uncertain due to the absence of ultimate efficacy improvement and..."

Journal • Cholestasis • Hepatology • Infertility

Composition for Treating Uterine Fibroid (SB-UF) (clinicaltrials.gov) - P4 | N=66 | Completed | Sponsor: Trieu, Nguyen Thi, M.D. | Trial completion date: Feb 2021 ➔ Dec 2025 | Trial primary completion date: Jan 2021 ➔ Dec 2025

Trial completion date • Trial primary completion date • Gynecology • Solid Tumor • Uterine Leiomyoma • Women's Health

Pharmacodynamic interaction analysis of dydrogesterone, progesterone, and estradiol in combination-progestin HRT frozen embryo transfer: a prospective clinical cohort study. (PubMed, Reprod Biol Endocrinol) - P | "This study introduces simultaneous dual-progestin quantification as a methodological platform for pharmacodynamic interaction research in HRT-FET. Exploratory interaction patterns between both progestins and estradiol suggest clinically relevant additive effects, while patterns between the two progestins are compatible with potential substitutive dynamics that can only be evaluated within combination regimens without analytical cross-reactivity. These findings provide a mechanistic framework and generate hypotheses for adequately powered prospective studies investigating joint hormone exposure and reproductive outcomes."

Journal • PK/PD data • MVP

Comparison of two menopausal hormone therapy regimens in managing menopausal symptoms: a retrospective study. (PubMed, BMC Womens Health) - "Femoston and Climen provide comparable short-term menopausal symptom relief. The more favorable lipid profile with Femoston, particularly its HDL-C benefit, may inform individualized regimen selection, especially in women without indications for antiandrogenic therapy. Prospective studies with longer follow-up are warranted to evaluate hard cardiovascular endpoints."

Journal • Retrospective data • Cardiovascular • CNS Disorders • Insomnia • Sleep Disorder

DYD-HCG: Comparison of Dydrogesterone Alone Versus Dydrogesterone Plus HCG in Threatened Miscarriage (clinicaltrials.gov) - P=N/A | N=100 | Completed | Sponsor: Pakistan Air Force (PAF) Hospital Islamabad

New trial